ReviewNeuromolecular medicine2008
Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.
Review in Neuromolecular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of plasma amyloid-β levels in Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2011Pooled it
- Effects of a staged integral art-based cognitive intervention (SIACI) program in older adults with cognitive impairments: protocol for a randomized controlled trial.BMC geriatrics · 2022Article
- Effect of memantine on expression of Bace1-as and Bace1 genes in STZ-induced Alzheimeric rats.Molecular biology reports · 2020Article
- Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.Molecular neurobiology · 2019Review
- Amyloidogenic Nanoplaques in Blood Serum of Patients with Alzheimer's Disease Revealed by Time-Resolved Thioflavin T Fluorescence Intensity Fluctuation Analysis.Journal of Alzheimer's disease : JAD · 2019Article
- Toward Exosome-Based Neuronal Diagnostic Devices.Micromachines · 2018Review
- Heparan sulfate proteoglycans mediate Aβ-induced oxidative stress and hypercontractility in cultured vascular smooth muscle cells.Molecular neurodegeneration · 2016Article
- Oral glucose tolerance testing to modulate plasma amyloid levels: A novel biomarker.Alzheimer's & dementia (Amsterdam, Netherlands) · 2015Article
- Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4⁺ T cells 10-20 years before men.Translational psychiatry · 2014Article
- Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease.International journal of geriatric psychiatry · 2013Article
- Potential blood biomarker for disease severity in the Taiwanese population with Alzheimer's disease.American journal of Alzheimer's disease and other dementias · 2013Article
- Vitamin D2-enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPswe/PS1dE9 transgenic mice.PloS one · 2013Article
- BACE1 as a potential biomarker for Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2011Review
- Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells.Molecular neurodegeneration · 2010Article
- Biomarkers in Alzheimer's disease: past, present and future.Biomarkers in medicine · 2010Review
- Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.Experimental gerontology · 2010Article
- Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-β in plasma.Journal of Alzheimer's disease : JAD · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Amyloid plaques are composed primarily of amyloid-beta (Abeta) peptides derived from proteolytic cleavage of amyloid precursor protein (APP) and are considered to play a pivotal role in Alzheimer's disease (AD) pathogenesis. Presently, AD is diagnosed after the onset of clinical manifestations. With the arrival of novel therapeutic agents for treatment of AD, there is an urgent need for biomarkers to detect early stages of AD. Measurement of plasma Abeta has been suggested as an inexpensive and non-invasive tool to diagnose AD and to monitor Abeta modifying therapies. However, the majority of cross-sectional studies on plasma Abeta levels in humans have not shown differences between individuals with AD compared to controls. Similarly, cross-sectional studies of mouse plasma Abeta have yielded inconsistent trends in different mouse models. However, longitudinal studies appear to be more promising in humans. Recently, efforts to modify plasma Abeta levels using modulators have shown some promise. In this review, we will summarize the present data on plasma Abeta in humans and mouse models of AD. We will discuss the potential of modulators of Abeta levels in plasma, including antibodies and insulin, and the challenges associated with measuring plasma Abeta. Modulators of plasma Abeta may provide an important tool to optimize plasma Abeta levels and may improve the diagnostic potential of this approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.